|
TBRG1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.85984561085206E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.10329983932434E-10 |
| Normal-vs-Stage2 |
5.15260000000239E-07 |
| Normal-vs-Stage3 |
2.52020626589911E-14 |
| Normal-vs-Stage4 |
3.48480133638418E-11 |
| Stage1-vs-Stage2 |
6.101200E-01 |
| Stage1-vs-Stage3 |
2.579200E-04 |
| Stage1-vs-Stage4 |
3.598900E-03 |
| Stage2-vs-Stage3 |
5.260000E-02 |
| Stage2-vs-Stage4 |
7.819600E-02 |
| Stage3-vs-Stage4 |
9.048200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5976109324356E-13 |
| Normal-vs-AfricanAmerican |
8.66910000008048E-07 |
| Normal-vs-Asian |
1.363280E-04 |
| Caucasian-vs-AfricanAmerican |
5.251600E-01 |
| Caucasian-vs-Asian |
2.273900E-02 |
| AfricanAmerican-vs-Asian |
5.492200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.39919989325688E-10 |
| Normal-vs-Female |
2.03614902716254E-12 |
| Male-vs-Female |
9.733400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.0883000056694E-09 |
| Normal-vs-Age(41-60Yrs) |
1.18529963621938E-10 |
| Normal-vs-Age(61-80Yrs) |
1.80389037041095E-12 |
| Normal-vs-Age(81-100Yrs) |
2.16720000001391E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.682830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.323800E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.429700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.542000E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.167830E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.082200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.72129999997939E-06 |
| Classical-VS-Follicular |
9.779000E-01 |
| Classical-VS-Other |
6.697800E-01 |
| Classical-VS-Normal |
6.08819661351845E-11 |
| Tall-VS-Follicular |
1.019810E-04 |
| Tall-VS-Other |
8.280100E-02 |
| Tall-VS-Normal |
1.27675647831893E-14 |
| Follicular-VS-Other |
7.180400E-01 |
| Follicular-VS-Normal |
2.54960000001248E-07 |
| Other-VS-Normal |
4.782400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.48709982900664E-11 |
| Normal-vs-N1 |
1.64729999996283E-06 |
| N0-vs-N1 |
7.059800E-01 |
|
|
